ALSO NOTED: GW Pharma must mount new trials; Elan shares surge on Tysabri strategy; and much more...

> GW Pharma confirmed reports that regulators will require the company to mount new clinical trials to confirm the safety of its cannabis-based Sativex. Story

> Shares of Elan and Biogen Idec surged late Thursday after the New England Journal fo Medicine quoted doctors for Biogen discussing strategies to return Tysabri to the market while protecting patients from a possible brain infection. Story

> The European Commission has approved Schering-Plough's Temodal for first-line use for the treatment of newly diagnosed glioblastoma multiforme, the most common and aggressive form of primary brain cancer. Release

> The FDA has extended its review of Insmed's Somatokine for three months, until October 3. Release

And Finally... Drug makers believe a proposed new law on patents could make life harder for the industry. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.